Adial Pharmaceuticals(US:ADIL) Globenewswire·2025-10-17 13:00Core Viewpoint - Adial Pharmaceuticals, Inc. is gaining visibility through CEO Cary Claiborne's appearance on the Big Biz Show, which could enhance the company's profile in the biopharmaceutical industry focused on addiction treatment [1][2]. Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing therapies for addiction and related disorders [3]. - The company's lead product, AD04, is a genetically targeted serotonin-3 receptor antagonist aimed at treating Alcohol Use Disorder (AUD) in heavy drinking patients [3]. - AD04 has shown promising results in the ONWARD™ pivotal Phase 3 clinical trial, demonstrating effectiveness in reducing drinking among heavy drinkers without significant safety or tolerability issues [3]. - The potential applications of AD04 extend to other addictive disorders, including Opioid Use Disorder, gambling, and obesity [3].